SonoVision Ultrasound Imaging System
Tissue Differentiation Intelligence, LLC • Radiology • 03/12/2020
Device Purpose
The SonoVision™ Ultrasound Imaging System with its Beluga1™ probe is engineered to provide real-time, intraoperative visualization and evaluation of nerves, vascular, and other anatomical structures, with a specific emphasis on aiding spinal procedures through B-mode and Doppler imaging. Its methodology relies on a 10 MHz transducer, specialized image processing software for enhanced anatomical definition, and an ergonomically designed probe, all validated through comprehensive non-clinical safety and performance testing as well as in vivo human application studies.
Summary
The SonoVision™ Ultrasound Imaging System, developed by Tissue Differentiation Intelligence, LLC, is a general-purpose ultrasound system designed for qualified physicians to visualize and evaluate nerves, vascular structures, and other anatomical features, particularly offering imaging assistance for spinal procedures. The system comprises the SonoVision™ console and monitor, the Beluga1™ 10 MHz transducer imaging probe—ergonomically designed for intraoperative use and specifically developed for spine applications—and control software, which includes image processing capabilities to define anatomical features in B-mode ultrasound images. The SonoVision™ system employs B-mode imaging and Doppler/color flow mapping for real-time 2-D scanning and differentiation of bone and tissue. It utilizes radiofrequency energy for its internal functions with low RF emissions, features a non-user adjustable acoustic output, a reusable probe, proprietary software, and supports data capture and external storage. Non-clinical testing confirmed its performance, acoustic output, biocompatibility, cleaning, sterilization, and safety (thermal, electrical, electromagnetic, mechanical) against various standards, while in vivo clinical testing was conducted to demonstrate its performance in human applications.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the image processing software specifically aid in defining anatomical features during intraoperative spinal procedures compared to systems without this specialized feature?; What are the specific ergonomic advantages of the Beluga1™ probe design for intraoperative use, particularly in the confined spaces encountered during spine surgery?; Can the system's 'tissue differentiation' capability provide quantitative metrics for tissue characterization, or is it primarily a qualitative visual enhancement for the physician?; What were the key performance outcomes of the in vivo human application testing, especially regarding the accuracy and resolution of nerve and vascular visualization in complex spinal anatomies?; Given its 'general purpose' designation alongside its specific development for spine procedures, what is the performance efficacy and utility of the SonoVision™ system in other non-spinal intraoperative applications requiring detailed anatomical visualization?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, ML-BOM, SaaSBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly